The What Million Dollar Question: Patent Litigation And Strategy Under The Biologics Price Competition And Innovation Act | 4446
ISSN: 2157-7625

Journal of Ecosystem & Ecography
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Indexed In
  • CAS Source Index (CASSI)
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Online Access to Research in the Environment (OARE)
  • Open J Gate
  • Genamics JournalSeek
  • Ulrich's Periodicals Directory
  • Access to Global Online Research in Agriculture (AGORA)
  • Electronic Journals Library
  • RefSeek
  • Hamdard University
  • OCLC- WorldCat
  • SWB online catalog
  • Virtual Library of Biology (vifabio)
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
Share This Page

The what million dollar question: Patent litigation and strategy under the Biologics Price Competition and Innovation Act

Biodiversity & Sustainable Energy Development-2012

Bryan J. Vogel

Posters: J Ecosyst Ecogr

DOI: 10.4172/2157-7625.S1.009

The Biologics Price Competition and Innovation Act of 2009 (?BPCIA?) has a regulatory and dispute resolution framework inspired by the framework set forth for small-molecule generics under the Hatch-Waxman Act. While similarities do exist, fundamental differences between the two regulatory frameworks will mean that the first originator and follow-on biosimilar manufacturers working their way through the process set forth in the BPCIA will be in uncharted and potentially time- consuming and costly waters. The proposed talk will review the fundamentals of the BPCIA regulatory framework and the system of disclosures and counter-disclosures required when an application to manufacturer a biosimilar raises the possibility of a claim for patent infringement. It will also highlight the areas where experience gained in prior patent litigation involving generics will likely apply and those areas where that experience may be inapplicable. Specific areas of consideration include patent portfolio management and protection under the BPCIA?s evolving process, pre-litigation patent information disclosures, oversight and verification of required disclosures and validation, and the shared and specific patent-related challenges originator and biosimilar manufacturers will face.
Bryan J. Vogel is a partner in the New York office of the law firm of Robins, Kaplan, Miller, & Ciresi L.L.P. He is an Intellectual Property litigator with a practice emphasis in Life Sciences and Hatch-Waxman and biosimilars ligation and strategic counseling. He publishes frequently on general Intellectual Property topics, as well as matters specific to the Life Sciences community. He received his J.D. from George Washington University. In addition, he earned a B.S. in Chemical Engineering, with honors from Michigan State University, where he was also a member of Phi Beta Kappa and Tau Beta Pi (invited)
Relevant Topics